GT
HZNP

Glenmede Trust’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Glenmede Trust’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-388
Closed -$30K – 2573
2020
Q3 		$30K Sell
388
-652,194
-100% -$44.9M ﹤0.01% 1464
2020
Q2 		$36.3M Sell
652,582
-725,010
-53% -$31M 0.22% 114
2020
Q1 		$49.9M Hold
1,377,592
– – 0.23% 121
2019
Q4 		$49.9M Sell
1,377,592
-178,641
-11% -$5.48M 0.23% 121
2019
Q3 		$42.4M Sell
1,556,233
-130,116
-8% -$3.36M 0.19% 142
2019
Q2 		$40.6M Sell
1,686,349
-315,846
-16% -$8.01M 0.18% 156
2019
Q1 		$52.9M Sell
2,002,195
-257,532
-11% -$6.1M 0.24% 115
2018
Q4 		$44.2M Sell
2,259,727
-191,974
-8% -$3.76M 0.22% 125
2018
Q3 		$48M Sell
2,451,701
-828,766
-25% -$15.8M 0.19% 163
2018
Q2 		$54.3M Sell
3,280,467
-358,706
-10% -$5.47M 0.24% 111
2018
Q1 		$53.1M Hold
3,639,173
– – 0.22% 124
2017
Q4 		$53.1M Sell
3,639,173
-317,808
-8% -$4.46M 0.22% 124
2017
Q3 		$50.2M Buy
3,956,981
+2,763,561
+232% +$35.1M 0.22% 132
2017
Q2 		$17.6M Hold
1,193,420
– – 0.08% 310
2017
Q1 		$17.6M Buy
1,193,420
+52,882
+5% +$856K 0.08% 310
2016
Q4 		$18.5M Sell
1,140,538
-909,661
-44% -$16.5M 0.1% 301
2016
Q3 		$37.2M Buy
+2,050,199
New +$40.1M 0.21% 143
2015
Q3 		– Sell
-542,278
Closed -$18.8M – 2891
2015
Q2 		$18.8M Sell
542,278
-511,863
-49% -$15.6M 0.14% 249
2015
Q1 		$27.4M Buy
+1,054,141
New +$19.3M 0.2% 153
2014
Q3 		– Sell
-2,335
Closed -$36K – 2537
2014
Q2 		$36K Buy
+2,335
New +$33.3K ﹤0.01% 1728

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Glenmede Trust's HZNP Position: Q4 2020 in Review

Glenmede Trust sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2020, closing a stake of 388 shares — an estimated $30K sold.

Glenmede Trust first reported a position in HZNP in Q2 2014 and held it in 20 quarters. The position peaked at $54.3M in Q2 2018. 497 funds tracked by Wall St. Rank hold HZNP as of Q4 2020.

  • Glenmede Trust reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 388 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2020, an estimated $30K.
  • Glenmede Trust first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2014 and held it in 20 quarters.
  • Glenmede Trust's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $54.3M in Q2 2018.
  • 497 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.